Ferroptosis has recently been identified as a potential therapeutic target for patients with NASH (Shu et al., 2022; Nelson et al., 2011; Wei et al., 2020), and inhibiting hepatic iron accumulation has demonstrated notable effectiveness in ameliorating insulin resistance, promoting insulin secretion, and recovering abnormal liver enzyme levels (Mou et al., 2019). Here, INS is linked to metabolic dysfunction-associated steatohepatitis.